Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma

Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop

(2021) Elaine Chang et al.   Nature Reviews Urology

Censored patients in Kaplan–Meier plots of cancer drugs: An empirical analysis of data sharing

(2020) Kate Rosen et al.   EUROPEAN JOURNAL OF CANCER

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

(2019) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review

(2018) Omar Abdel-Rahman   Immunotherapy

On the Interpretation of the Hazard Ratio and Communication of Survival Benefit

(2017) Andreas Sashegyi et al.   ONCOLOGIST

Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results

(2017) Dae Hyun Kim et al.   JAMA Cardiology

Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator

(2016) SJW Willems et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma

(2011) M. D. Galsky et al.   ANNALS OF ONCOLOGY

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

(2011) Maria De Santis et al.   JOURNAL OF CLINICAL ONCOLOGY

Mean and median survival times of cancer patients should be corrected for informative censoring

(2009) Karri Seppä et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Endpoints for Assessing Drug Activity in Clinical Trials

(2008) R. Pazdur   ONCOLOGIST